H.C. Wainwright Sticks to Their Buy Rating for Codexis (CDXS)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Codexis (CDXSResearch Report) today and set a price target of $22.50. The company’s shares closed last Monday at $15.32.

According to TipRanks.com, Ramakanth has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.2% and a 31.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals, ThermoGenesis Holdings, and IntelGenx Technologies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Codexis with a $22.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $23.05 and a one-year low of $12.68. Currently, Codexis has an average volume of 412.7K.

Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CDXS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics.